WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 596652
Description: L 691831 is a radioiodinated inhibitor of leukotriene synthesis.
MedKoo Cat#: 596652
Name: L 691831
Chemical Formula: C36H38N2O4
Exact Mass: 562.2832
Molecular Weight: 562.71
Elemental Analysis: C, 76.84; H, 6.81; N, 4.98; O, 11.37
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: L 691831; L-691831; L691831; L-691,831; L 691,831; L691,831;
IUPAC/Chemical Name: 3-(1-benzyl-3-(3,3-dimethylbutanoyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropanoic acid
InChi Key: APLNXIHARZQHIK-UHFFFAOYSA-N
InChi Code: InChI=1S/C36H38N2O4/c1-35(2,3)21-32(39)33-28-19-27(42-23-26-16-15-25-13-9-10-14-29(25)37-26)17-18-30(28)38(22-24-11-7-6-8-12-24)31(33)20-36(4,5)34(40)41/h6-19H,20-23H2,1-5H3,(H,40,41)
SMILES Code: O=C(O)C(C)(C)CC(N1CC2=CC=CC=C2)=C(C(CC(C)(C)C)=O)C3=C1C=CC(OCC4=NC5=CC=CC=C5C=C4)=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 562.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Macdonald D, Brideau C, Chan CC, Falgueyret JP, Frenette R, Guay J, Hutchinson JH, Perrier H, Prasit P, Riendeau D, Tagari P, Thérien M, Young RN, Girard Y. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein. Bioorg Med Chem Lett. 2008 Mar 15;18(6):2023-7. doi: 10.1016/j.bmcl.2008.01.105. Epub 2008 Feb 2. PubMed PMID: 18276139.
2: Charleson S, Evans JF, Léger S, Perrier H, Prasit P, Wang Z, Vickers PJ. Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein. Eur J Pharmacol. 1994 May 17;267(3):275-80. PubMed PMID: 8088366.
3: Mancini JA, Coppolino MG, Klassen JH, Charleson S, Vickers PJ. The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein. Life Sci. 1994;54(9):PL137-42. PubMed PMID: 8114608.
4: Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers PJ. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 1993 Mar 8;318(3):277-81. PubMed PMID: 8440384.
5: Charleson S, Prasit P, Léger S, Gillard JW, Vickers PJ, Mancini JA, Charleson P, Guay J, Ford-Hutchinson AW, Evans JF. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol Pharmacol. 1992 May;41(5):873-9. PubMed PMID: 1588922.